Add Yahoo as a preferred source to see more of our stories on Google. Whether you suffer from psoriasis yourself or have heard about it from a famous Kardashian who has been very transparent about her ...

When I was first diagnosed with psoriasis, I assumed I would need a ton of expensive prescription treatments or to overhaul my entire life in order to manage it. But I learned over time not to ...

Did you know that more than 7 million people in the U.S. have psoriasis? It may not be as well known or talked about as other skin conditions like eczema or rosacea, but it's something that a lot of ...

Findings showed that 88.5% of patients achieved target lesion Physician Global Assessment success at week 12. Tapinarof cream was found to be an effective treatment for plaque psoriasis of the head ...

Psoriasis is a chronic inflammatory skin disease characterized by erythematous (red) patches and plaques. In some patients, psoriasis may be associated with comorbidities such as arthritis, obesity, ...

Psoriasis can begin at any age, but typically appears around 15 to 25 years of age and 50 to 60 years of age. The exact cause of psoriasis is not known, but risk factors and triggers may include ...

Please provide your email address to receive an email when new articles are posted on . Arcutis Biotherapeutics announced positive results from two pivotal phase 3 studies evaluating Zoryve cream as a ...

A PDUFA target date of June 29, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for roflumilast cream 0.3% for ...

Arcutis Biotherapeutics has spent the weeks since the FDA approval of its topical plaque psoriasis cream Zoryve strengthening its cash position, drawing down $125 million from its loan facility and ...

Hot off its first approval this summer in psoriasis, Arcutis Biotherapeutics’ roflumilast foam 0.3%, approved in cream form under the brand name Zoryve, is out to prove it’s no one-trick pony in itch.

Data from the INTEGUMENT trials demonstrates that ZORYVE cream 0.15% has a favorable safety profile and high tolerability, even among patients with prior inadequate responses to traditional treatments ...

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces that ...